Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GDTC 
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: GDTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.92% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.16M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.36 | 52 Weeks Range 1.65 - 4.05 | Updated Date 10/22/2025 |
52 Weeks Range 1.65 - 4.05 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date 2025-09-30 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -452.17% |
Management Effectiveness
Return on Assets (TTM) -22.85% | Return on Equity (TTM) -42.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21747993 | Price to Sales(TTM) 41.32 |
Enterprise Value 21747993 | Price to Sales(TTM) 41.32 | ||
Enterprise Value to Revenue 372.15 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11733712 | Shares Floating 3593787 |
Shares Outstanding 11733712 | Shares Floating 3593787 | ||
Percent Insiders 68.09 | Percent Institutions 0.43 |
Upturn AI SWOT
CytoMed Therapeutics Limited Ordinary Shares
Company Overview
History and Background
CytoMed Therapeutics Limited is a Singapore-based biotechnology company focused on developing novel cell-based immunotherapies for the treatment of cancers. Founded in 2018, the company leverages its proprietary technologies to engineer immune cells to target and eliminate cancer cells. CytoMed is listed on the Nasdaq under the ticker symbol GDTC.
Core Business Areas
- CAR-CIK Therapy: Development of Chimeric Antigen Receptor Cytokine-Induced Killer (CAR-CIK) cell therapies for solid tumors. This is a key focus area.
- Gamma Delta T Cell Therapy: Development of gamma delta T cell therapies for various cancers. This innovative approach targets cancer cells based on their stress signals.
- Antibody Drug Conjugates: Development of Antibody Drug Conjugates (ADCs) to target cancer cells.
Leadership and Structure
The company is led by a team of scientists and business executives with experience in cell therapy and drug development. They report to a board of directors overseeing the company's strategic direction.
Top Products and Market Share
Key Offerings
- CAR-CIK (CM-CD19-CAR-CIK): CM-CD19-CAR-CIK is CytoMed's lead product candidate, targeting CD19-positive B-cell lymphomas and lekemias. It is currently in clinical trials. Specific market share data is not yet available, as the product is pre-commercialization. Competitors in the CAR-T therapy space include Novartis (Kymriah) and Gilead (Yescarta).
- Gamma Delta T Cell Therapy (CM-GDT-001): CM-GDT-001 utilizes genetically engineered gamma delta T cells that are engineered to express proteins or antibodies to enhance their cancer killing ability. It is in pre-clinical development. Specific market share data is not yet available, as the product is pre-commercialization. Competing therapies include conventional chemotherapy and other immuno-oncology approaches.
Market Dynamics
Industry Overview
The cell therapy industry is experiencing rapid growth, driven by advances in genetic engineering and immunology. The immuno-oncology market is expanding significantly with a substantial amount of capital being invested in next generation immuno-oncology therapies.
Positioning
CytoMed Therapeutics Limited Ordinary Shares is a player in the cell therapy space, focusing on CAR-CIK and gamma delta T cell therapies. Their competitive advantage lies in their innovative approaches and proprietary technologies within these niche areas.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is projected to reach billions of dollars in the coming years. CytoMed is positioning itself to capture a portion of this market with its innovative therapies, starting with lymphoma.
Upturn SWOT Analysis
Strengths
- Proprietary CAR-CIK and gamma delta T cell technologies
- Strong scientific team
- Focus on innovative cell-based immunotherapies
- Clinical stage product candidate
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early stage development pipeline
- Dependence on clinical trial success
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline to other cancer types
- Positive clinical trial results
- Advancements in cell therapy technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- JNJ
Competitive Landscape
CytoMed competes with larger pharmaceutical companies in the cell therapy space. Its advantages include its innovative technologies and focus on niche markets. Its disadvantages include limited financial resources and an early stage development pipeline.
Growth Trajectory and Initiatives
Historical Growth: CytoMed is a young company. Historical growth is measured by progress in its R&D pipeline and clinical trials.
Future Projections: Future growth is tied to successful clinical trial results and partnerships. Analyst estimates depend on these factors.
Recent Initiatives: Recent initiatives include advancing CM-CD19-CAR-CIK in clinical trials and expanding the gamma delta T cell therapy program.
Summary
CytoMed Therapeutics is a pre-revenue biotechnology company focused on innovative cell-based immunotherapies. Its strength lies in its proprietary technologies. It needs to achieve positive clinical trial results and establish partnerships to compete effectively with larger pharmaceutical companies. Cash burn and competition are key risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change. This analysis relies on publicly available information and assumptions that may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://w2.cytomed.sg |
Full time employees 43 | Website https://w2.cytomed.sg | ||
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.